Stroke is a long-term disability and one of the leading causes of death. However, no successful therapeutic intervention is available for the majority of stroke patients. In this study, we explored a traditional Chinese medicine Baifuzi (Typhonium giganteum Engl.). We show, at first, that the ethanol extract of Baifuzi exerts neuroprotective effects against brain damage induced by transient global or focal cerebral ischemia in rats and mice. Second, the extract activated large-conductance Ca 2 þ -activated K þ channel (BK Ca ) channels, and BK Ca channel blockade suppressed the neuroprotection of the extract, suggesting that the BK Ca is the molecular target of Baifuzi. Third, Baifuzi cerebroside (Baifuzi-CB), purified from its ethanol extract, activated BK Ca channels in a manner similar to that of the extract. Fourth, the stress axis hormone-regulated exon (STREX) domain of the BK Ca channel directly interacted with Baifuzi-CB, and its deletion suppressed channel activation by Baifuzi-CB. These results indicate that Baifuzi-CB activated the BK Ca channel through its direct interaction with the STREX domain of the channel and suggests that Baifuzi-CB merits exploration as a potential therapeutic agent for treating brain ischemia. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits distribution and reproduction in any medium, provided the original author and source are credited. This license does not permit commercial exploitation without specific permission.
Stroke is a devastating condition that annually affects 15 million people worldwide, and is the leading cause of adult disability in industrialized countries. 1 Although there has been progress in our understanding of the pathophysiology of stroke during the past few decades, stroke continues to pose major therapeutic challenges, both to neuroscientists and to clinicians. 2 For example, a large number of neuroprotective agents have been shown to successfully reduce infarct size in animal models of stroke, but they have failed to demonstrate efficacy in phase III clinical trials in humans. 3 To date, no successful therapeutic interventions are available for the majority of stroke patients. 1, 3 The intravenous recombinant tissue plasminogen activator (rt-PA) is the only drug therapy available for thrombolytic treatment of stroke in the United States, Canada and Europe. However, the requirement to exclude hemorrhagic stroke and the restriction to use within 3 h of the onset of symptoms limit rt-PA therapy to only B2% of all stroke patients. 1 Therefore, there is an urgent need for new therapeutic options for the treatment of stroke.
One of the options that might offer fertile ground for modern drug development is traditional medicines, because traditional medicines, such as traditional Chinese medicine (TCM), have long time since documented the effects of many natural products on humans, and extensive human experience can provide some degree of comfort with regard to their safety. 4 Clinical application of artemisinin, triptolide, celastrol, capsaicin and curcumin has demonstrated the power and promise of turning traditional medicines into modern drugs. One of the most recent examples is veregen, an extract of green tea leaves, which was approved in 2006 by the US Food and Drug Administration as a new drug to treat perianal and genital condyloma. 5 As a matter of fact, more than half of the pharmaceutical drugs are either natural products or their derivatives.
Dried tubers of the herb Typhonium giganteum Engl. (Chinese name: Baifuzi), as a TCM, has been recorded in Chinese pharmacopeia and used for the treatment of brain stroke for a long time. 7 However, unlike industrially manufactured pharmacological drugs used in Western medicine, its active components and molecular targets have not been specified. Obviously, identification of its effects on welldefined molecular targets and the subsequent identification of its active component(s) underlying these effects are important for the evaluation of its therapeutic efficacy. Brain ischemia begins with energy depletion, followed by the disruption of ion homeostasis, membrane depolarization, excessive neurotransmitter (glutamate) release and elevation of intracellular calcium, all of which initiate a neurotoxic cascade that results in neurodegeneration and death of ischemic neurons. 8, 9 The large-conductance Ca 2 þ -activated K þ (BK Ca ) channels are widely expressed in the brain 10 and are preferentially located at glutamatergic synaptic terminals. 11, 12 They react to either increases in intracellular Ca 2 þ or membrane depolarization by increasing K þ efflux. Thus, they function as an 'emergency break' to limit Ca 2 þ influx for regulating synaptic transmission under conditions of enhanced neuronal excitability. 13 It has been shown that activation of BK Ca channels in ischemic cells by BK Ca channel openers could minimize neuronal depolarization, limit accumulation of potentially pathological levels of Ca 2 þ from a number of potential sources, reduce neurotransmitter release and significantly attenuate infarct growth during ischemic stroke in animal models. 14, 15 In addition, blockade of BK Ca channels enhanced cell damage in organotypical slice cultures after oxygen and glucose deprivation. 16 In this study, we show that the ethanol extract of Baifuzi (e-Baifuzi) shows significant neuronal protective activity in the rat and mice model of ischemic stroke. Second, we show that the BK Ca channel is the molecular target of the ethanol extract. Third, we identified that Baifuzi cerebroside (Baifuzi-CB) is the active component of Baifuzi in activating the BK Ca channel. Finally, we show that the stress axis hormone-regulated exon (STREX) domain of the BK Ca channel, a 59-amino-acid splice insertion located in the cytoplasmic side of the channel, is required for the activation of the BK Ca channel by Baifuzi-CB, probably due to direct interaction between Baifuzi-CB and the STREX domain.
Results e-Baifuzi protects ischemia-induced brain injury e-Baifuzi against ischemia-induced neuronal cell death. Transient global ischemia leads to a dramatic loss of neurons in the CA1 region of the hippocampus. 17, 18 Therefore, we examined whether e-Baifuzi has neuroprotective roles in the CA1 region in the rat model of transient global ischemia, which was made by 20 min 4-vessel occlusion (4VO). In the CA1 region of the ischemic hemisphere, the number of pyramidal neurons on the eighth day post-4VO was o50% of the control (2VO rats, n ¼ 8, Po0.01; Figures 1a and b) . Surprisingly, a single injection of e-Baifuzi (5 or 50 mg/kg) at 1 h post-4VO significantly attenuated neuronal loss in a dose-dependent manner (versus vehicle-treated 4VO rats, n ¼ 8, Po0.01), although no neuroprotective effect was observed at a dosage of 1 mg/ kg (P40.05). In contrast, the administration of e-Baifuzi at a dosage of 5 mg/kg did not affect the number of pyramidal neurons in 2VO rats (n ¼ 8, P40.05). Furthermore, the administration of e-Baifuzi (5 mg/kg) even at 4-8 h post-4VO also significantly reduced ischemia-induced neuronal loss (versus vehicle-treated 4VO rats, n ¼ 8, Po0.01; Figure 1c) , whereas it could not protect neuronal cells when administered at 24 h post-4VO (n ¼ 8, P40.05). These results suggested that e-Baifuzi could protect the brain from transient global cerebral ischemia and that its therapeutic time window may last up to 8 h after the onset of ischemia.
e-Baifuzi improves ischemia-induced deficits in spatial memory. Neuronal damage induced by transient global ischemia is accompanied by severe impairments in performance on hippocampally dependent spatial learning tasks. 19 To investigate whether e-Baifuzi could improve the behavioral disorder induced by transient global cerebral ischemia, we evaluated its effects on the performance of rats in a Morris water maze test. Results showed that rats subjected to 20 min global cerebral ischemia (4VO) significantly extended the escape latency to the hidden platform compared with 2VO rats (n ¼ 8, Po0.01; Figure 1d ), whereas the swimming speed was not detectably different between them (data not shown). In agreement with its neuroprotection, e-Baifuzi (5 mg/kg) reduced ischemiainduced prolongation of the escape latency when administered between 1 and 8 h post-4VO (versus vehicletreated 4VO rats, n ¼ 8, Po0.01). In contrast, it did not affect the escape latency of 2VO rats at a dosage of 5 mg/kg (n ¼ 8, P40.05). Thus, e-Baifuzi could improve spatial memory impairment induced by global cerebral ischemia.
e-Baifuzi reduces MCAO-produced cerebral infarction. To determine the effect of e-Baifuzi against focal cerebral ischemia-induced injury, we used a mouse model of middle cerebral artery occlusion (MCAO) by the intraluminal filament insertion technique. Infarct size was measured at 24 h of reperfusion as described previously. 20 As shown in Figure 2a and b, a single injection of e-Baifuzi (5 mg/kg) at 1 h post-MCAO remarkably reduced the hemispheric infarct, from 42 ± 2% in vehicle (saline)-injected MCAO mice (n ¼ 10) to 19 ± 5% in e-Baifuzi-injected MCAO mice (n ¼ 11, Po0.01), indicating that e-Baifuzi could reduce cerebral infarct induced by focal ischemia-induced damage.
e-Baifuzi protects the brain from ischemic injury through activation of BK Ca channels e-Baifuzi activates BK Ca channels. The above study confirmed the protective role of e-Baifuzi in ischemic injury. As BK Ca channels have been shown to have an important role in ischemic stroke, 14, 15 we explored whether the BK Ca channel is a potential target for the effect of e-Baifuzi. Wholecell configuration was used to investigate the effect of e-Baifuzi on the whole-cell currents of BK Ca channels expressed in CHO cells. All test experiments (n ¼ 28) showed an increase in current amplitude with the application of e-Baifuzi. Figure 3a clearly shows increases in whole-cell BK Ca channel currents from the same cell in response to e-Baifuzi at a concentration of 0.45 mg/ml. At a voltage of þ 100 mV, 0.45 mg/ml e-Baifuzi increased the current two and threefold at an intracellular Ca 2 þ concentration of 0.1 and 1 mM, respectively (Figure 3b ). At the single channel level, e-Baifuzi increased the single channel open probability (P o ) from 2.1±0.9% of control (n ¼ 11) to 18.4 ± 6.3% in the presence of 0.45 mg/ml e-Baifuzi (n ¼ 8) without affecting its amplitude (Figure 3c and d) . These results indicated that e-Baifuzi could activate the BK Ca channel and implied that the BK Ca channel is the molecular target of Baifuzi. e-Baifuzi reduces presynaptic glutamate release. Excessive glutamate release and subsequent excitotoxicity are major pathological factors leading to neurodegeneration and death of ischemic neurons. 8, 21 Previous studies have reported that BK Ca channels located at glutamatergic presynaptic terminals 12 regulate presynaptic Ca 2 þ entry, 10 which in turn regulates presynaptic glutamate release. 11 Therefore, we investigated the effect of e-Baifuzi on presynaptic glutamate release. First, the excitatory postsynaptic potential (EPSP) slopes in the presence of e-Baifuzi (0.45 mg/ml) were consistently less than those in its absence ( Figure 4a , Po0.05; n ¼ 10 slices per 5 rats). In addition, the reduction of the EPSP slope completely recovered within 10 min after e-Baifuzi washout (n ¼ 12 slices per 6 rats; Figure 4b ), indicating that e-Baifuzi reversibly suppresses synaptic transmission. Second, paired-pulse facilitation (PPF), a sensitive indicator of presynaptic glutamate release, was measured by delivering two successive stimuli with 25-150 interpulse intervals (IPIs). Compared with that before the addition of e-Baifuzi, the paired-pulse ratio (PPR) at 50-75 IPI was markedly increased after addition of e-Baifuzi (0.45 mg/ml) (Po0.05, n ¼ 15 slices per 7 rats; Figure 4c ). Furthermore, we measured the synaptically induced glial depolarization (SIGD), an indicator of the amount of presynaptic glutamate release, 22 in the presence of CNQX (10 mM)/AP5 (50 mM) (see the 'Materials and Methods' section). Consistent with the result of PPF, the area of SIGD was significantly reduced by perfusion of eBaifuzi (0.45 mg/ml) (Po0.05, n ¼ 12 slices per 6 mice), and could be recovered after the washout of e-Baifuzi (Figure 4d ). Thus, e-Baifuzi could reversibly reduce presynaptic glutamate release, which in turn might protect the brain from the excitotoxicity of excessive glutamate release.
Blockade of BK Ca channels abolishes the neuroprotection and glutamate release induced by e-Baifuzi. If the BK Ca channel is the molecular target, then its blocker should suppress the neuroprotective effect of e-Baifuzi. To determine whether the neuroprotection of e-Baifuzi is associated with BK Ca channel activation, charybdotoxin (CTX, 400 nM) was administered (i.v.c) for 30 min before the injection of e-Baifuzi (5 mg/kg) at 1 h post-4VO. Blockade of the BK Ca channel by CTX pretreatment significantly prevented the neuroprotection of e-Baifuzi (Figure 5a , Po0.01, n ¼ 8), whereas CTX alone had no significant effect on either 2VO or 4VO rats in comparison with the corresponding vehicletreated control groups. As CTX is a specific blocker of the BK Ca channel, the result strongly suggests that the BK Ca channel is the molecular target of e-Baifuzi for its neuroprotective effect. Furthermore, we found that administration of 100 nM CTX could prevent e-Baifuzi from reducing the area of SIGD (Po0.05, n ¼ 12 slices per 6 rats; Figure 5b ). These results strongly suggest that e-Baifuzi protects ischemia-induced brain injury by opening BK Ca channels to decrease presynaptic glutamate release, and gives further evidence that the BK Ca channel is the molecular target of Baifuzi.
Baifuzi-CB is the major active ingredient
The above studies indicated that e-Baifuzi had a significant neuroprotective effect on the ischemic brain through activation of BK Ca channels. This result prompted us to seek the active ingredient(s) of Baifuzi. We isolated Baifuzi-CB from e-Baifuzi, 23 which was verified by 1 H and 13 C NMR spectra ( Supplementary Figures 1b and c) . They appeared as one point on a normal silica gel thin layer chromatography (TLC) plate (Supplementary Figure 1a) . Although phytochemical studies have shown that Baifuzi contains several other chemicals, including amino acids, fatty acids, choline, uracil, daucosterol and dipalmin, 23 we began our studies by focusing on Baifuzi-CB, because our previous study showed that sulfatide, a kind of cerebroside, can potently activate BK Ca channels. 24 In whole-cell patch-clamp recordings, Baifuzi-CB dose-dependently increased BK Ca channel currents. Intracellular application of 10 mM Baifuzi-CB increased the relative BK Ca channel current (I/I o ) from 0.80±0.06 of control to Figure 6b ), suggesting that the action site of Baifuzi-CB is easier to access from the intracellular side. To examine whether the activation of BK Ca channels by Baifuzi-CB was due to some diffusible intracellular signal molecules, the effect of Baifuzi-CB on BK Ca channels was further examined at a single channel level in excised outside-out patches. As shown in Figure 6c , application of 10 mM Baifuzi-CB to the outside-out patch enhanced P o from 3.1±1.7% to 12.0±3.2%. Activation of BK Ca channels by Baifuzi-CB in patches excised from the cell membrane strongly suggests that their actions are not mediated by diffusible intracellular signal molecules. On the basis of the amount of Baifuzi-CB purified from e-Baifuzi, it is calculated that e-Baifuzi contains 0.87% of Baifuzi-CB. Thus, 0.45 mg/ml of Figure 3a and 6b, the channel activated by 10 mM Baifuzi-CB is at the same level as that of 0.45 mg/ml eBaifuzi, indicating that Baifuzi-CB is the major active component responsible for the activation of the BK Ca channel.
Molecular mechanism of BK Ca channel activation by Baifuzi-CB STREX is required for BK Ca channel activation by Baifuzi-CB. It has been shown in our previous studies that STREX is important for activation of BK Ca channels by lipid-soluble chemicals. 24, 25 Besides, it has been demonstrated that inclusion of the STREX exon facilitates voltage-and Ca 2 þ -dependent activation of BK Ca channels. 26 To test whether STREX contributes to the activation of the BK Ca channel by Baifuzi-CB, we studied its effect on the STREX-deleted mutant of the channel. Both intracellularly (1 mM, Figure 7 ) and extracellularly (10 mM, Figure 6b ) applied Baifuzi-CB significantly increased whole-cell current for wild-type BK Ca channels. The relative whole-cell current was increased from 0.80 ± 0.06 of control to 1.57 ± 0.28 in the presence of 1 mM Baifuzi-CB applied intracellularly (Figure 7b) , whereas extracellularly applied Baifuzi-CB (10 mM) increased the current from 0.70 ± 0.06 of control to 1.31 ± 0.15 ( Figure 6b ). In contrast, the STREX-deleted mutant BK Ca channel could not be activated by Baifuzi-CB, whether it was applied intracellularly (Figure 7b ) or extracellularly ( Supplementary Figure 2) , indicating that STREX is required for BK Ca channel activation by Baifuzi-CB.
Interaction between Baifuzi-CB and STREX. We investigated the manner in which Baifuzi-CB is sensed by STREX, which is located at the cytoplasmic side, to activate the BK Ca channel. A simple explanation may be that STREX interacts directly with Baifuzi-CB and consequently conveys the signal to gate the channel. To test whether the STREX domain is sufficient for Baifuzi-CB binding, we performed a protein lipid overlay (PLO) assay. No interaction was detected between STREX and POPE (1-Palmitoyl-2-Oleoylsn-Glycero-3-Phosphoethanolamine), 1-Palmitoyl-2-Oleoylsn-Glycero-3-[Phospho-rac-(1-glycerol (POPG) or DL-aPhosphatidylcholine Dipalmitoyl (DPPC). In contrast, the STREX domain of the BK Ca channel could interact with both (Figure 8a ), indicating that Baifuzi-CB can bind to the BK Ca channel through its STREX domain. Interestingly, Baifuzi-CB and e-Baifuzi, which can bind to STREX, could activate the channel (Figure 3 and Figure 6 ), whereas POPE, POPG and DPPC, which cannot bind to STREX could not activate the channel (Figures 8b and d) . These results strongly suggest that the interaction with the STREX domain is critical for BK Ca channel activation by Baifuzi-CB. If this is true, then the overexpression of STREX fragments will interrupt the interaction between Baifuzi-CB and the STREX domain of the channel, which might subsequently suppress the ability of Baifuzi-CB to activate the channel. To confirm this hypothesis, the STREX fragment was overexpressed with BK Ca channels (BK Ca /STREX ¼ 1 : 2, q/q). This overexpression significantly inhibited the ability of Baifuzi-CB to activate the channel (Figure 8c and d) . This result further confirmed that the BK Ca channel activated by Baifuzi-CB is through its interaction with the STREX domain of the channel.
Discussion
In this study, we show that e-Baifuzi protects ischemiainduced brain injury through activation of BK Ca channels, which in turn could reduce the excitotoxic glutamate release at the condition of brain ischemia. This conclusion is supported by the following four results: (1) e-Baifuzi protected ischemiainduced brain injury in a dose-dependent manner when administered after global or focal cerebral ischemia in rats and mice. (2) e-Baifuzi activated the BK Ca channel by increasing its P o without affecting its amplitude. (3) The neuroprotective effect of e-Baifuzi could be suppressed by the specific blocker of BK Ca channels. (4) e-Baifuzi suppressed presynaptic glutamate release through the activation of BK Ca channels in hippocampal slices.
Furthermore, we propose that the BK Ca channel activated by Baifuzi-CB is through the interaction between Baifuzi-CB and the STREX domain of the BK Ca channel according to the following pieces of evidence: (1) PLO assay indicated the direct interaction between Baifuzi-CB and the STREX domain; (2) the STREX domain is required for activation of the BK Ca channel by Baifuzi-CB, indicating that the interaction between the STREX domain and Baifuzi-CB is critical for channel activation. This is in accordance with the result that intracellular application of Baifuzi-CB is more effective than that applied extracellularly. Many BK Ca channel modulators have been reported to prevent neuronal degeneration after ischemia in preclinical studies. However, there is no approval of a single BK Ca channel modulator for clinical use so far. For example, BMS-204352, one of the potent BK Ca channel activators described to prevent neuronal degeneration after ischemia, has failed to improve the clinical outcome in patients affected by stroke. 27 In this study, we demonstrated that Baifuzi could effectively reduce brain damage in both focal and global ischemia. We are aware that there is no guarantee that Baifuzi will be effective in the clinical treatment of stroke. However, the following reasons may suggest its potential of being regarded as a therapeutic agent: (1) Baifuzi has been effectively used for the treatment of brain stroke for a long time in China 7 . (2) Cerebrosides are rich in the brain, implying that Baifuzi-CB may have a target-specific effect on neurons. (3) As an analog of membrane cerebroside, Baifuzi-CB may be transported by the endogenous transport machinery to target cells to fulfill its action.
Lipid-protein interactions are of fundamental importance, as they partly determine the structures of integral membrane proteins and their activities. 28 Lipid regulation of channels has been demonstrated for NMDA receptor channels, 29, 30 TRAAK channels, 31 transient receptor potential channels, 32 inward rectifier K þ channels, 33 Ca 2 þ channels, 34 voltage-dependent K þ channels, 35 BK Ca channels 36, 37 and Twik-related K þ channels. 38 The KcsA potassium channel only opens if the membrane contains a small amount of an anionic lipid, and lipid association has actually been resolved in the crystal structure of KcsA K þ channels. 39 Therefore, it is not surprising that Baifuzi-CB can activate BK Ca channels. In agreement with this result, we have previously found that sulfatide, a kind of cerebroside, can potently activate BK Ca channels. 24 In this study, we found that the BK Ca channel can be activated by Baifuzi-CB even at the excised membrane, implying that channel activation was not due to some intracellular diffusible signals. Besides, Baifuzi-CB could not increase at the intracellular Ca 2 þ level in hippocampal neurons (data not shown), suggesting that BK Ca channel activation is not due to an increase in intracellular Ca 2 þ concentration. Then, how does Baifuzi-CB activate the channel? There are at least three possibilities, which are not exclusive with each other: (1) The STREX domain of the BK Ca channel is attracted toward the plasma membrane because of the direct interaction with Baifuzi-CB, leading to a stabilization of the open state. This is similar to what has been proposed for the PI(4,5)P 2 -dependent gating of inward-rectifier K þ channels. 40 (2) Baifuzi-CB alters the thickness of the membrane, and thus makes the BK Ca channel easy to open. This mechanism has been shown for BK Ca channel activation by phosphatidylcholines (PCs) of varying chain lengths. 41 (3) Baifuzi-CB may create stress in the membrane because of its large head group, as we reported previously for the BK Ca channel activated by membrane stress created with amphipaths. 25 Obviously, further studies are required to judge which one or their combinations is correct.
In both global and focal ischemia, restriction of blood flow to the brain limits the delivery of oxygen and glucose to neurons, causing energy depletion. This is followed by a cascade of neurochemical events, including disruption of ion homeostasis, excessive release of glutamate, overload of intracellular Ca 2 þ , release of free radicals, inflammatory changes and finally cell death of neurons, glia and endothelial cells. 9, 42 These injury cascades are interconnected in complex ways, as one event in the cascade can cause or can be caused by multiple other events, and cells suffering from different severity levels of ischemia may undergo different chemical processes. On the other hand, AKT has been shown to have a prominent part in signaling networks that result in the modulation of cellular proliferation, apoptosis and survival. Recently, activation of AKT has been demonstrated to be important in neuronal survival after cerebral ischemia. [43] [44] [45] [46] The neuroprotective effects of nerve growth factor, osteopontin, erythropoietin, as well as preconditioning and postconditioning to reduce ischemia-induced brain injury, are mediated by AKT [47] [48] [49] [50] . In our study, we demonstrated that Baifuzi could activate the BK Ca channel and reduce the release of glutamate, which is responsible for the neuroprotective effect of Baifuzi. Therefore, it would be very interesting to study whether the AKT pathway is involved in the effect of Baifuzi on brain ischemia.
In summary, we demonstrated that e-Baifuzi provided significant neuroprotection, not only in protecting neurons against cell death but also in promoting behavioral recovery in the animal model of stroke. We identified the BK Ca channel as a molecular target for the therapeutic action of Baifuzi, and that Baifuzi-CB is the active component that effectively activates BK Ca channels. Through BK Ca channel activation, e-Baifuzi limited glutamate release, which is involved in excitotoxicity during ischemic damage. These data provide evidence that e-Baifuzi attenuates ischemia-induced neuronal damage by enhancing the activation of BK Ca channels. Its neuronal protective effect provides pharmacological rationale for the traditional use of Baifuzi in stroke. As the natural source of Baifuzi, the medicinal tubers of T. giganteum Engl., has a long history in Chinese traditional medicine, it is hoped that Baifuzi-CB will be a well tolerated, promising therapeutic candidate for the treatment of ischemic brain stroke and other forms of neuronal damage.
Materials and Methods
Extraction and isolation. Tubers of Baifuzi were collected from Yuxian County (Henan Province, China). The dried material was powdered and then extracted with 95% ethanol for several days with shaking. The extract was concentrated to yield e-Baifuzi. e-Baifuzi was chromatographed on silica gel, then on ODS to afford Baifuzi-CB, which was confirmed to be a mixture of cerebrosides on the basis of 1 H and 13 C NMR spectra (Supplementary Figure 1b and c) . TLC experiment indicated that Baifuzi-CB is one of the major spots of e-Baifuzi (Supplementary Figure 1a) . The detailed process was described in our previous paper. 23 Experimental animals. Male Sprague-Dawley rats (weighing 200-250 g, Oriental Bio Service Inc., Nanjing, China) and male mice (weighing 25-30 g, Oriental Bio Service Inc.) were used throughout the study. Animals were housed in a light-controlled room under a 12 h light-dark cycle starting at 0700 hours and kept at 251C. They were given unrestricted access to food and water. All procedures were in accordance with the guidelines of the Institute for Laboratory Animal Research of the Nanjing Medical University.
Preparation of the global brain ischemia model. We used a 4VO method for transient global ischemia as described elsewhere. 51 Briefly, using sodium pentobarbital anesthesia (60 mg/kg, intraperitoneally (i.p.)), both common carotid arteries (CCAs) of rats were dissected free, and the incision was closed. Immediately after this procedure, both vertebral arteries (VAs) between the first and second cervical vertebrae were exposed and electro-cauterized completely using a bipolar cauterizer under an operating microscope (SZH-ILLB, Olympus, Tokyo, Japan). After 24 h, the common arteries were occluded with aneurysm clips for 20 min. The clips were then removed, and blood flow though the arteries was confirmed before the wound was sutured. Rectal temperature was continually monitored and maintained at B371C using a heating pad until the animal had fully recovered from anesthesia. Sham operation (control) groups had a permanent bilateral occlusion of VAs (2VO rats) that was carried out in the same manner as in 4VO rats, except that the CCAs were not occluded. All rats were allowed to survive for 8 days after the onset of cerebral ischemia.
Preparation of the focal cerebral ischemia model. Focal cerebral ischemia was induced by MCAO for 60 min using the intraluminal filament insertion technique, as described previously. 52 All mice were anesthetized with 2% halothane, and were then maintained with 1% halothane in 70% N 2 O and 30% O 2 using a vaporizer. Briefly, a poly-L-lysine (0.1% per weight volume)-coated nylon monofilament thread (3/0 G with the tip heat blunted to a diameter of 0.104 mm) was inserted through the external carotid artery and advanced into the internal carotid artery to occlude the origin of the MCA (B12 mm). Adequacy of vascular occlusion and reperfusion was monitored in the front parietal cortex of the occluded side by Perimed PF5050 (Perimed, Jarfalla, Sweden) multichannel laser Doppler flowmetry. Body and head temperatures were monitored and controlled at 37±0.51C using a homeothermic blanket and water pads. Arterial blood pressure and gases were monitored through a femoral catheter. After 60 min of occlusion, the filament was withdrawn to allow for reperfusion, and animals recovered from anesthesia and survived for 24 h. Sham-operated animals were treated identically, except that MCAs were not occluded after the neck incision.
Drug administration. Animals subjected to cerebral ischemia treatment or sham operation were blinded to drug-treated groups. e-Baifuzi was diluted in 0.9% saline to a final concentration of 1.0% ethanol that was used as vehicle control. CTX, a BK Ca channel blocker, was dissolved in 0.9% saline and injected into the cereboventricle (i.c.v.). e-Baifuzi was administered i.p. For i.c.v. implantation, mice were anesthetized with ketamine (80 mg/kg i.p.). A guide cannula (4 mm length, 23 G) aimed above the left lateral ventricle was implanted and anchored to the skull with four stainless steel screws and dental cement. The guide cannula was implanted above the rostral ventricle so as to not lesion the hippocampus. The drug was prepared freshly on the day of the experiment and injected using a steppermotorized microsyringe (Stoelting, Wood Dale, IL, USA) at a rate of 0.5 ml/min (final volume ¼ 3 ml per mouse). Control mice were given an equal volume of vehicle.
Histological examination after 4VO. On the eighth day post-4VO, all animals were deeply anesthetized with pentobarbital (50 mg/kg) and were perfused transcardially with ice-cold phosphate-buffered saline (PBS), followed by 4% icecold phosphate-buffered paraformaldehyde. The brains were removed, postfixed in the same fixative for 24 h and then processed for paraffin embedding. Coronal sections (4 mm in thickness) including the dorsal hippocampus were cut and stained with toluidine blue. All slide preparations were randomly coded so that observers were blind to the experimental condition. Healthy CA1 pyramidal neurons, showing a round cell body with a plainly stained nucleus, were counted by eye using a conventional light microscope (PD70) with a 100 Â objective. The number of surviving pyramidal neurons per 1 mm length along the extent of the CA1 pyramidal layer was counted as neuronal density (cells per mm) as described elsewhere. 53 We also conducted supplemental examinations on several slices stained with trypan blue that stains dead cells, and obtained results that were essentially the same as that determined by eye with the toluidine blue-stained slices. To exclude the possibility that alterations in cell density value might be a consequence of changes in the volume of reference, we used a subset of the sections for volume estimation of CA1 stratum radiatum using Scion Image software (Scion Corp., Frederick, MD, USA). Six slices were prepared from the right and left dorsal hippocampus each to count the number of surviving pyramidal neurons.
Lesion size measurement after MCAO. Using 2,3,5-triphenyltetrazolium chloride (TTC) staining, we measured the infarct size at 24 h of reperfusion, as described previously. 20 All animals were killed under deep halothane anesthesia, and the brains were quickly frozen and sliced into thick sections for infarct measurement. Tissue infarction was identified by TTC staining in thick (2 mm) coronal sections. Slices were photographed, and images were studied using imageanalysis software (MCID; Imaging Research, St. Catharines, ON, Canada). The infarct volume in all slices was expressed as a percentage of the contralateral hemisphere after correcting for edema.
Behavioral analysis. Animals were trained in the standard Morris water maze task 54 . For the Morris water maze task, a pool (90 cm diameter, 45 cm height) made of black-colored plastic was prepared, and was filled with water (20±11C) that was rendered opaque with nontoxic blue paint. Swimming paths were analyzed by a computer system using a video camera (AXIS-90 Target/2; Neuroscience, Inc., Tokyo, Japan). In the hidden-platform test, the platform (7 cm in diameter) was submerged 1 cm below the water surface. The first day of training began with a free swim, in which the swim speed was assessed in the absence of the platform, and then immediately after the free swim, mice were given four training trials per day over 5 days, in which they were given 90 s to swim to the hidden platform. If a mouse did not find the platform in the allotted time, it was placed on the platform for 15 s. The average swim speed (cm/s) and latency (s) to reach the platform were scored on all trials and analyzed. Data were obtained from groups of 10 mice throughout the experiments.
Electrophysiological analysis Slice preparation. Rats were decapitated under deep anesthesia with ethyl ether. Brains were rapidly removed and coronal brain slices (400 mm) were cut using a vibrating microtome (Microslicer DTK 1500, Dousaka EM Co., Kyoto, Japan) in ice-cold cutting solution composed of (in mM) 94 sucrose, 30 NaCl, 4.5 KCl, 1.0 MgCl 2 , 26 NaHCO 3 , 1.2 NaH 2 PO 4 , and 10 D-glucose with pH 7.4. The hippocampal slices were continuously incubated in artificial cerebrospinal fluid (ACSF) at 36 ± 11C for more than 60 min to allow the slices to recover. ACSF was composed of (in mM) 124 NaCl, 2 CaCl 2 , 4.5 KCl, 1 MgCl 2 , 26 NaHCO 3 , 1.2 NaH 2 PO 4 , and 10 D-glucose. pH was adjusted to 7.4. Both the cutting solution and ACSF were oxygenated with a gas mixture of 95% O 2 and 5% CO 2 .
Field potential recording. For recordings, the slice was transferred into a recording chamber and perfused continuously with oxygenated ACSF at a flow rate of B1 ml/min. The experiments were conducted at 30 ± 11C. Briefly, orthodromic stimuli were delivered using an electrically polished bipolar tungsten electrode that was placed in the outer third of the molecular stratum of hippocampal dentate gyrus to stimulate the lateral perforant path. Constant current pulses (0.05 Hz) were supplied by a stimulator (SEN-3301, Nihon Kohden, Tokyo, Japan). EPSP was recorded from the middle third of the molecular stratum with a 4-5 MO resistance glass microelectrode that was filled with 0.9% NaCl and connected to a neutralized, high input-impedance preamplifier with a high-pass filter at 5 kHz. The level of test stimulus was set to evoke B50% of a minimum stimulus intensity that evoked a saturated EPSP in each slice to avoid possible deprivation of readily releasable transmitters. Signals were amplified using a differential AC amplifier (A-M Systems, model 1700, Seattle, WA, USA). EPSPs were digitized and saved using the pCLAMP system (Axon Instrument Inc., Foster City, CA, USA). Stability of baseline recordings was established by delivering single pulses (1 per min, 0.1 ms pulse width at an intensity yielding half-maximal EPSP amplitude for a given slice) for 15-30 min before collection of input/output functions. Baseline synaptic transmission was assessed by averaging the response to five pulses (from 0.1 to 1.0 mA) delivered at a rate of 0.05 Hz. PPF was examined at a range of IPIs (25-150 ms) and a stimulus intensity of half-maximal for elicitation of EPSP.
Optical recordings. All slices used in optical recording were stained with a voltage-sensitive dye (RH155 0.2 mg/ml, Nippon Kanko Shikiso Kenkyujo, Okayama, Japan) for 15 min, and were kept in a chamber containing oxygenated ACSF for at least 30 min for recovery as described previously. 55 The slices were then transferred into a recording chamber and placed on the stage of an Olympus inverted microscope (IMT-2, Nikon, Tokyo, Japan). Test stimulus was set at 50% maximal stimulus intensity to evoke optical EPSP (op-EPSP) in each slice. Light from a tungsten-halogen lamp (type JC-24v/200 W, Kondo Philips, Tokyo, Japan) was collimated, and an interference filter with a transmission maximum at 700 ± 10 nm (Olympus Optical, Tokyo, Japan) was used. Changes in light absorption associated with membrane potential changes were measured using an optical recording system equipped with a high-speed diode camera with metal oxide (MOS) image sensors (128 Â 128 pixels, each of which receives light from a 25 mm Â 25 mm sample area) and a data processing unit (HR Deltaron-1700 Fujix; Fuji Photo Film, Tokyo, Japan). To minimize bleaching of the dye molecules and photodynamic damages to slices, a heat-absorption filter was placed on the slices, and the light path to the slice was opened only long enough to measure optical responses (1-2 s). In each trial, a background image recorded for 16 ms before electrical stimulation was stored as a reference image. To analyze the change in neuronal activities over time at a given region, data from each pixel were stored and retrieved, and the amplitude of the optical signal (indicated as a percentage change in optical absorbency) was plotted as a function of time. Signals obtained from six pixels in str. molecular were averaged. RH155 dye is reported to stain glial cells preferentially over neuronal cells. 56 Optical recording with the RH155 dye is used to monitor glial depolarization by the electrogenic glutamate transporter (GLT-1) uptaking the released glutamate. 57 When AMPA and NMDA receptors are blocked, a delayed depolarizing response can be recorded, which is completely abolished by the specific GLT-1 blocker. Thus, the size of SIGD is considered to reflect the probability of presynaptic glutamate release. Compensation for cell capacitance and series resistance was made automatically using EPC-9 or EPC-10 amplifiers; only recordings with stable series resistances p25 MO were included in the study. Currents were amplified using EPC-9 or EPC-10 patch-clamp amplifiers (HEKA, Lambrecht, Germany), sampled at 2-5 kHz and filtered at 1.5-2.9 kHz using a 4-pole low-pass Bessel filter. Program packages Patchmaster 2.1 and TAC 4.1 (HEKA) were used for data acquisition and analysis. The probability of a single channel being open (P o ) was simply calculated from the total time spent in the open state divided by the total time of recording for the patches containing a single channel. Continuous recordings of 2000-4000 ms were used to estimate P o . When multiple channels were present in a patch, P o was calculated from the amplitude histogram as P o ¼ (1ÀP C 1/N ), where P C is the fraction of area under the closed state, and N is the number of channels. To avoid underestimating the number of channels in a patch as less as possible, the number of active single channels in the patch was counted at the condition in which the maximum number of channels was observed. Both e-Baifuzi and Baifuzi-CB activate chick BK Ca expressed in CHO cells, as well as rat BK Ca expressed in HEK293 cells, at both the single channel and whole-cell level. However, for convenience, we present data at the single channel level for chick BK Ca and at the whole-cell level for rat BK Ca channels. Both e-Baifuzi and Baifuzi-CB have low aqueous solubility and were dissolved in 100% dimethyl sulfoxide (DMSO) as a stock solution and diluted with intracellular or extracellular solutions to obtain different concentrations as required. The final concentration of DMSO was o0.5% per assay, which had no effect on the BK Ca channel.
Plasmid construction and STREX-SBP fusion protein purification. The STREX gene of the chick BK Ca channel was amplified from pcDNA 3.1-BK Ca and subcloned into PQE30( þ ) (Novagen, Madison, WI, USA). The STREX-SBP (streptavidin-binding peptide) fusion protein was constructed by insertion of a peptide linker (Ser-Gly) 5 between the STREX and SBP tag. After culturing in LB medium containing 0.1 mg/ml ampicillin at 371C and 200 r.p.m./min, cells were induced to express the STREX-SBP fusion protein by adding 0.25 mM IPTG until OD 600 ¼ 0.4. Cells were harvested by centrifugation at 8000 r.p.m./min for 10 min, ultrasonicated and centrifuged at 12 000 r.p.m./min for 30 min at 41C to remove the cell fragments. The supernatant was applied to a Ni2 þ -NTA column (Amersham Life Sciences, Buckinghamshire, UK). Gradient imidazole was then used to elute the protein. Its purity was analyzed by SDS-PAGE. The purified protein was stored in buffer containing 50 mM Tris-HCl, pH 8.2, 200 mM NaCl, 1 mM 1,4-dithiothreitol (DTT) and 20% glycerol at À701C until use.
